Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 2092-2103.e6

  Chachay, Veronique S ^a,b   Macdonald, Graeme A ^a,b   Martin, Jennifer H ^a   Whitehead, Jonathan P ^c   O'Moore Sullivan, Trisha M ^a,b   Lee, Paul ^a,b   Franklin, Michael ^b   Klein, Kerenaftali ^a   Taylor, Paul J ^b   Ferguson, Maree ^a,b   Coombes, Jeff S ^a   Thomas, Gethin P ^a   Cowin, Gary J ^a   Kirkpatrick, Carl M J ^d   Prins, Johannes B ^a,c   Hickman, Ingrid J ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ALT; AST; Chronic Disease; NAFLD; Obesity Related Fatty Liver

Indexed keywords

ALANINE; ASPARTATE AMINOTRANSFERASE; HO1 PROTEIN; INTERLEUKIN 6; LIPID; MEMBRANE PROTEIN; NQO1 PROTEIN; PLACEBO; PROTEIN TYROSINE PHOSPHATASE 1B; RESVERATROL; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; STILBENE DERIVATIVE;

ABDOMINAL FAT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; AUSTRALIA; CALORIC RESTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SAFETY; FATTY LIVER; GENETIC TRANSCRIPTION; HUMAN; IMAGE ANALYSIS; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; METABOLIC CAPACITY; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; RESTING ENERGY EXPENDITURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ABDOMINAL FAT; ADULT; AGED; AUSTRALIA; GASTROINTESTINAL AGENTS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLACEBOS; STILBENES; TREATMENT OUTCOME;

EID: 84918791665     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.024     Document Type: Article

References (69)

1. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
2. Vernon G., Baranova A., Younossi Z. Systematic review: the epidemiology and natural history of non alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
3. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
4. Bonora E., Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012, 9:372-381.
5. Schuppan D., Gorrell M.D., Klein T., et al. The challenge of developing novel pharmacological therapies for non alcoholic steatohepatitis. Liver Int 2010, 30:795-808.
6. Cowin G.J., Jonsson J.R., Bauer J.D., et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. JMagn Reson Imaging 2008, 28:937-945.
7. Promrat K., Kleiner D., Niemeier H., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
8. Osland E.J., Powell E.E., Banks M., et al. Obesity management in liver clinics: translation of research into clinical practice. JGastroenterol Hepatol 2007, 22:504-509.
9. Utzschneider K.M., Kahn S.E. The role of insulin resistance in nonalcoholic fatty liver disease. JClin Endocrinol Metab 2006, 91:4753-4761.
10. Wieser V., Moschen A.R., Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Archivum Immunologiae et Therapiae Experimentalis 2013, 61:1-7.
11. de Wit N.J., Afman L.A., Mensink M., et al. Phenotyping the effect of diet on non-alcoholic fatty liver disease. JHepatol 2012, 57:1370-1373.
12. Mouzaki M., Allard J.P. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. JClin Gastroenterol 2012, 46:457-467.
13. Cardozo L.F., Pedruzzi L.M., Stenvinkel P., et al. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. Biochimie 2013, 95:1525-1533.
14. Shapiro H., Tehilla M., Attal-Singer J., et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011, 30:6-19.
15. Wu C.F., Yang J.Y., Wang F., et al. Resveratrol: botanical origin, pharmacological activity and applications. Chinese Journal of Natural Medicines 2013, 11:1-15.
16. Chachay V.S., Kirkpatrick C.M., Hickman I.J., et al. Resveratrol-pills to replace a healthy diet?. Br J Clin Pharmacol 2011, 72:27-38.
17. Smoliga J.M., Vang O., Baur J.A. Challenges of translating basic research into therapeutics: resveratrol as an example. JGerontol A Biol Sci Med Sci 2012, 67:158-167.
18. Baur J., Pearson K., Price N., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
19. Lagouge M., Argmann C., Gerhart-Hines Z., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 [alpha]. Cell 2006, 127:1109-1122.
20. Price N.L., Gomes A.P., Ling A.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012, 15:675-690.
21. Ahn J., Cho I., Kim S., et al. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. JHepatol 2008, 49:1019-1028.
22. Bujanda L., Hijona E., Larzabal M., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
23. Gómez-Zorita S., Fernández-Quintela A., Macarulla M., et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012, 107:202.
24. Shang J., Chen L.L., Xiao F.X., et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica 2008, 29:698-706.
25. Patel K.R., Scott E., Brown V.A., et al. Clinical trials of resveratrol. Ann N Y Acad Sci 2011, 1215:161-169.
26. Brasnyó P., Molnár G.A., Mohás M., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Aktpathway in type 2 diabetic patients. Br J Nutr 2011, 106:383-389.
27. Crandall J.P., Oram V., Trandafirescu G., et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. JGerontol A Biol Sci Med Sci 2012, 67:1307-1312.
28. Ghanim H., Sia C., Abuaysheh S., et al. An anti-inflammatory and reactive oxygen species suppressive effects of an extract of polygonum cuspidatum containing resveratrol. JClin Endocrinol Metab 2010, 95:E1.
29. Poulsen M.M., Vestergaard P.F., Clasen B.F., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
30. Timmers S., Konings E., Bilet L., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
31. Yoshino J., Conte C., Fontana L., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012, 16:658-664.
32. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659.
33. Crowell J., Korytko P., Morrissey R., et al. Resveratrol-associated renal toxicity. Toxicol Sci 2004, 82:614.
34. USFDA. Guidance for industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research, USFDA, US Department of Health and Human Services. 2005. Available at: . Accessed December 20, 2013. http://www.fda.gov/ohrms/dockets/98fr/02d-0492-gdl0002.pdf.
35. la Porte C., Voduc N., Zhang G., et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010, 49:449-454.
36. DeFronzo R., Tobin J., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Gastrointest Liver Physiol 1979, 237:214.
37. Croci I., Byrne N.M., Choquette S., et al. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut 2013, 62:1625-1633.
38. Matthews D., Hosker J., Rudenski A., et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
39. Gastaldelli A., Natali A., Vettor R., et al. Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig Liver Dis 2010, 42:310-319.
40. Kenna T.J., Davidson S.I., Duan R., et al. Enrichment of circulating interleukin 17-secreting interleukin 23 receptor-positive γ/δ Tcells in patients with active ankylosing spondylitis. Arthritis Rheum 2012, 64:1420-1429.
41. Luo X., Hutley L.J., Webster J.A., et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI) as a potent negative regulator of adipogenesis and modulator of autocrine/paracrine adipogenic factors. Diabetes 2012, 61:124-136.
42. Magkos F., Fabbrini E., Korenblat K., et al. Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. Int J Obes 2010, 35:1233-1240.
43. Detampel P., Beck M., Krähenbühl S., et al. Drug interaction potential of resveratrol. Drug Metab Rev 2012, 44:253-265.
44. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research 2012, 32:537-541.
45. Movahed A., Nabipour I., Lieben Louis X., et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine 2013, 2013:851267.
46. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. JClin Invest 2001, 108:1167-1174.
47. Tomé-Carneiro J., Larrosa M., González-Sarrías A., et al. Resveratrol and clinical trials: the crossroad from invitro studies to human evidence. Curr Pharm Des 2013, 19:6064-6093.
48. Sun C., Zhang F., Ge X., et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6:307-319.
49. Tomé-Carneiro J., Gonzálvez M., Larrosa M., et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013, 27:37-48.
50. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
51. Hou X., Xu S., Maitland-Toolan K., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. JBiol Chem 2008, 283:20015.
52. Lasa A., Schweiger M., Kotzbeck P., et al. Resveratrol regulates lipolysis via adipose triglyceride lipase. JNutr Biochem 2012, 23:379-384.
53. Ghanim H., Sia C.L., Korzeniewski K., et al. Aresveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. JClin Endocrinol Metab 2011, 96:1409-1414.
54. Han P., Duffull S., Kirkpatrick C., et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007, 82:505-508.
55. Kyle U.G., Bosaeus I., De Lorenzo A.D., et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr 2004, 23:1430-1453.
56. Brown V., Patel K., Viskaduraki M., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 2010, 70:9003-9011.
57. Borel P. Factors affecting intestinal absorption of highly lipophilic food microconstituents (fat-soluble vitamins, carotenoids and phytosterols). Clin Chem Lab Med 2003, 41:979-994.
58. Sandstrom B. Micronutrient interactions: effects on absorption and bioavailability. Br J Nutr 2001, 85:S181.
59. Sharma V., McNeill J.H. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009, 157:907-921.
60. Green B., Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol 2004, 58:119-133.
61. Martin J.H., Saleem M., Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity: a new use for an old methodology. Br J Clin Pharmacol 2012, 73:685-690.
62. Calabrese E.J., Mattson M.P., Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 2010, 29:980-1015.
63. Patel K., Brown V., Jones D., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010, 70:7392.
64. El-Mohsen M.A., Bayele H., Kuhnle G., et al. Distribution of [3H] trans-resveratrol in rat tissues following oral administration. Br J Nutr 2006, 96:62-70.
65. Chung J.H., Manganiello V., Dyck J.R. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol 2012, 22:546-554.
66. Gescher A., Steward W.P., Brown K. Resveratrol in the management of human cancer: how strong is the clinical evidence?. Ann N Y Acad Sci 2013, 1290:12-20.
67. Aires V., Limagne E., Cotte A.K., et al. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Molecular Nutrition and Food Research 2013, 57:1170-1181.
68. Patel K.R., Andreadi C., Britton R.G., et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Science Translational Medicine 2013, 5. 205ra133-205ra133.
69. Calabrese E.J., Mattson M.P. Hormesis provides a generalized quantitative estimate of biological plasticity. Journal of Cell Communication and Signaling 2011, 5:25-38.